Antimicrobial Susceptibility Pattern of Community Acquired Pneumonia among Adults in Tripura, North-Eastern India

Dr. Mousumi Paul\textsuperscript{1*}, Dr. Tapan Majumdar\textsuperscript{2}, Dr. Pradip Bhowmik\textsuperscript{3}

\textsuperscript{1}Medical Officer-MD Microbiology, Department of Microbiology-Tripura Health Service, Agartala Government Medical College & GBP Hospital, Agartala, PIN no. 799006, Tripura
\textsuperscript{2}Professor and Head, Department of Microbiology, Agartala Government Medical College & GBP Hospital, Agartala, PIN no. 799006, Tripura
\textsuperscript{3}Professor, Department of Medicine, Agartala Government Medical College & GBP Hospital, Agartala, PIN no. 799006, Tripura

DOI: 10.36347/sjams.2020.v08i08.022 | Received: 18.08.2020 | Accepted: 25.08.2020 | Published: 28.08.2020

*Corresponding author: Dr. Mousumi Paul

Abstract

Community Acquired Pneumonia (CAP) is the most common respiratory tract infection in day to day practice. The knowledge of organism commonly causative of CAP helps in early empirical treatment initiation. The true incidence of pneumonia acquired in the community is unknown, but this is a common clinical problem worldwide especially in developing countries and remains a leading cause of death in India. There are very few and conflicting Indian data regarding the bacteriological etiology of community acquired pneumonia (CAP). Adding to this agony, there is no much credible data from the north-eastern part of India. Hence the following study was undertaken to study the aerobic bacteriological profile and antimicrobial susceptibility pattern of community-acquired pneumonia among adult. A total of 220 patients were studied. Age group varied from 18 years to 85 years. Most common organisms responsible were Klebsiella pneumonia, Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenzae, Streptococcus pneumoniae. Gram negative Organisms were found to be sensitive for Meropenem (100%), followed by Piperacillin-Tazobactum (87.95%), Amikacin (84.34%), Ceftriaxone (73.49%) and Levofloxacin (69.88%). Highest number of resistance was seen against Amoxyccillin-Clavulanic acid (74.39%), followed by Ceftazidime (66.67). For gram positive cocci, highest sensitivity was shown to Clindamycin (83.67%), followed by Doxycycline (81.63%) & Ceftriaxone (73.47%). \textit{Conclusion:} Klebsiella pneumoniae was the most common pathogen incriminated in CAP, followed by Staphylococcus aureus. Most of the organisms were found to be sensitive to carbapenem, third generation cephalosporins, fluoroquinolones, macrolides.

Keywords: North-eastern india, Community acquired pneumonia, antimicrobial susceptibility pattern, bacteriological profile.

INTRODUCTION

Pneumonia is defined as an acute respiratory illness associated with recently developed radiological pulmonary shadowing which may be segmental, lobar or multilobar. Pneumonia is usually classified as Community Acquired Pneumonia (CAP) and Hospital acquired pneumonia (HAP) [1].

Infectious Diseases Society of America (IDSA) defines CAP as “an acute infection of the pulmonary parenchyma that is associated with at least some symptoms of acute infection, accompanied by the presence of an acute infiltrate on a chest radiograph or auscultatory findings consistent with pneumonia in a patient not hospitalized or residing in a long-term care facility for more than 14 days before onset of symptoms” [2]. Around 20% of the mortality due to infectious diseases in India is caused by lower respiratory tract infections among which pneumonia is the most important culprit [3]. Bacteriological profile in community acquired pneumonia (CAP) is different in different countries and changes with time even within the same country. Looking at world literatures microbiological diagnosis could be made in only 40-71% of cases of CAP even when extensive methods have been used when compared to >90% cases in pre-antibiotic era [3]. The widespread antibiotic (mis) use is probably responsible for decreasing culture rates in CAP. The problem of pneumonia is much greater in developing countries where pneumonia is the most common cause of hospital attendance in adults [4]. Sir William Osler, known as "the father of modern medicine," appreciated the morbidity and mortality of pneumonia, describing it as the "captain of the men of death" in 1918. Pneumonia is a common illness.
affecting approximately 450 million people a year and occurring in all parts of the world. It is a major cause of death among all age groups resulting in 4 million deaths (7% of the world's total death) yearly [5].

As many as 4 million cases of CAP occur annually and 20% of them require hospitalization. The mortality ranges from 13.6% in hospitalized patients to 36.5% in patients admitted to ICU [6].

In India estimated death rate per 100,000 population in 2004 was 89.5% due to LRTI & estimated disability adjusted life years (DALYs) per 100,000 population in 2004 was 1894 [7].

Aetiology of CAP is generally bacterial but the microbial pattern varies from country to country. It varies with time and geographical distribution within the same country and so does the antimicrobial sensitivity and emerging resistance pattern. Streptococcus pneumoniae is the most common etiological agent in United Kingdom, Europe, United States of America and Iraq. In India Streptococcus pneumoniae is most common causative organism of pneumonia in Delhi, Shimla, Ludhiana and Pune [8, 9]. Staphylococcus aureus is the most common organism isolated in CAP at Manipur, India [10].

The treatment of CAP is complicated by growing threat of antimicrobial resistance and the tendency to rely on empirical therapy. Indiscriminate use of antibiotics has led us to emergence of multidrug resistant strains. The scenario is getting worsened day by day. Recent years have witnessed the emergence of new pathogens and also no newer antibiotics designed to combat them [11].

Most of organism are developing resistance to various antibiotics, now a day. The organism is mainly sensitive to third generation cephalosporins, fluoroquinolones and aminoglycosides [7]. The problem of resistance is leading to increased morbidity and mortality by increasing duration of hospital stay, rendering our therapy ineffective and by increasing the complications [12].

Although a wide variety of recognized pathogens cause CAP, the precise etiology, pattern of microbial flora in various settings, antibiotic sensitivity and resistance in India is still not comprehensively studied [13].

Empirical therapy should be guided by the antibiogram of a study conducted in a tertiary care hospital. The life threatening outcome of pneumonia underscores the importance of use of timely surveillance data to guide the effective choice of empirical therapy which will have a great impact on mortality & morbidity of patients.

In view of the above observations made by various workers, the present study is being conducted to know the causative agents of the CAP and to find out the antibiotic sensitivity pattern (antibiogram) of the causative organisms so that the patients are properly diagnosed and treated with specific antibiotics. Further, no similar studies has been carried out in this state. This study will also give us information regarding the occurrence, types of the causative bacterial agents their antibiogram, & socio-demographic profile of adult onset CAP patients in a tertiary care hospital in this state. Lastly the study will have an impact on the overall understanding & management of adult onset CAP & to reduce the mortality and morbidity of pneumonia in this state.

**MATERIAL AND METHODS**

The present study was conducted at Department of Microbiology in collaboration with the Department of Medicine of AGMC & GBP Hospital between December 2017 and June 2019. This study is a hospital based cross sectional study carried out on 220 cases of community-acquired pneumonia of patients aged ≥18 years. Prior to the study, the protocol was approved by the institutional ethical committee, and all patients gave their informed consent to participate.

Inclusion criteria were subjects aged ≥18 years old, outpatients with symptoms, signs and laboratory data diagnostic of pneumonia as well as inpatients with pneumonia at the time of hospitalization. Patients who had already received antibiotics before sputum could be sent for culture sensitivity, aspiration pneumonia, obstructive pneumonia, immune-compromised state, nosocomial pneumonia were excluded from the study

Sputum and bronchoalveolar lavage was collected for gram stain and culture and sensitivity, before starting empirical antibiotic therapy. Following gram staining those specimens were inoculated in Blood agar (BA), MacConkey agar (MA), Chocolate agar (CA). Inoculation in chocolate agar was done when pus cell count in direct gram staining was observed to be more than 50/hpf. The inoculated plates were incubated aerobically at 37°C overnight. The inoculated chocolate agar & sheep blood agar suspending growth for Streptococcus pneumoniae however were incubated at 5-10% CO₂ (candle jar) with similar duration and temperature.

**RESULTS**

The results and observations of the study are as follows

**Distribution of sample:** During the study period 216 sputum samples and 4 bronchoalveolar lavage samples were collected from a total of 220 study population (comprising of 122(55.45%) from IPD,75(34.10%) from OPD & 23(10.45%) from ICU) of community acquired pneumonia as per inclusion and exclusion criteria from medicine & chest department.
Distribution of study population according to severity score (CURB-65): 145 samples were collected from patients admitted in hospital (IPD & ICU) based on their pneumonia severity score – CURB 65 (Figure-1).

Sputum Microscopical examination: The sputum smears were gram stained and examined under microscope for determination of their adequacy. Out of 216 sputum samples, 165 samples showed >10 pus cells/epithelial cells under low power field in gram staining (Figure 2 & 3). Rest 51 sputum samples were recollected from patients and the adequacy of samples were revalidated. After validation of sputum samples bacteriological culture was done. Of those smears predominate organisms were, 39 (18.06%) gram positive cocci, 70 (32.41%) gram-negative bacilli, and 107 (49.54%) were mixed. Details are shown in Table-1.

Bacteriological culture and isolation: Out of 216 sputum samples, 127 (58.80 %) were found to be culture positive for bacterial isolates & respiratory commensals grew in 89 (41.20 %) samples. Among the 127 culture positive samples, 81 (63.78%) and 46(36.22%) were GNB and GPC respectively. Out of the 4 BAL samples, all (100%) were found to be culture positive, 1(25%) being GNB & the remaining 3(75%) were GPC.

The most common organism isolated from sputum culture was Klebsiella pneumoniae (n=44, 20.4%), followed by Staphylococcus aureus (n=35, 16.2%), Pseudomonas aeruginosa (n=18, 8.3%), Streptococcus pneumoniae (n=9, 4.2%), Citrobacter koseri (n=9, 4.2%), Escherichia coli (n=5, 2.3%), Citrobacter freundii (n=3, 1.4%), Streptococcus pyogenes (n=2, 0.9%), Haemophilus influenzae (n=2, 1%), whereas the 4 BAL samples comprised of Klebsiella pneumoniae (n=1, 25%) & Staphylococcus aureus (n=3, 75%) (Figure-4).

**Sputum gram staining and culture demonstrated correlation in 109 of 216 patients (with both gram staining and culture positivity and 89 patients had respiratory commensal grown in culture)

Antibiotic sensitivity testing: Out of 82 GNB isolated from sputum & BAL samples (81 & 1 respectively), 100% isolates were sensitive to Meropenem, followed by Piperacillin-Tazobactum (87.95%), Amikacin (84.34%), Ceftriaxone (73.49%) and Levofloxacin (69.88%). Highest number of resistance was seen against Amoxicillin-clavulanic acid (74.39%), followed by Cefazidine (66.67%) (Table-2).

For GPC (46 from sputum samples & 3 from BAL samples), highest sensitivity was shown to Clindamycin (83.67%), followed by Doxycycline (81.63%) & Ceftriaxone (73.47%), whereas maximum resistance was seen against Erythromycin (57.14%), followed by Amoxyclav (34.69%) (Table-3).

### Table-1: Sputum gram staining findings

| Gram staining (predominate organism) | No. of patients | Percentage (%) |
|-------------------------------------|----------------|----------------|
| Gram positive cocci                 | 39             | 18.06          |
| Gram negative bacilli               | 70             | 32.41          |
| Mixed organisms                     | 107            | 49.54          |

### Table-2: AST of various GNB

| Antibiotics | Organisms (Percentage of sensitivity) |
|-------------|----------------------------------------|
|             | K.pneumoniae (n=45) | P.aeruginosa (n=18) | C.koseri (n=9) | E.coli (n=5) | C.freundii (n=3) | H.influenzae (n=2) |
| AMC         | 26.67%(12)            | 22.22%(4)           | 33.33%(3)     | 20%(1)      | 33.33%(1)       | 100%(2)             |
| AK          | 84.44%(38)            | 88.86%(16)          | 88.89%(8)     | 100%(5)     | 66.67%(2)       |                     |
| CTR         | 75.56%(34)            | 72.22%(13)          | 88.89%(8)     | 60%(3)      | 66.67%(2)       |                     |
| LEV         | 71.11%(32)            | 66.67%(12)          | 77.78%(7)     | 40%(2)      | 33.33%(1)       | 100%(2)             |
| PIT         | 88.89%(40)            | 94.44%(17)          | 100%(9)       | 60%(3)      | 100%(3)         |                     |
| MRP         | 100%(45)              | 100%(18)            | 100%(9)       | 100%(5)     | 100%(3)         |                     |
| CAZ         | -                      | 33.33%(6)           | -             | -           | -               | 100%(2)             |
| CLR         | -                      | -                   | -             | -           | -               | 50%(1)              |
| CHL         | -                      | -                   | -             | -           | -               | 100%(2)             |
Table-3: AST of various GPC

| Antibiotics | Organisms (percentage of sensitivity) | Staphylococcus aureus (n=38) | Streptococcus pneumoniae (n=9) | Streptococcus pyogenes (n=2) |
|-------------|---------------------------------------|-----------------------------|-----------------------------|----------------------------|
| AMC         | 57.89% (22)                           | 88.89% (8)                  | 0% (0)                      |
| CD          | 81.58% (31)                           | 88.89% (8)                  | 0% (0)                      |
| LEV         | 57.89% (22)                           | 88.89% (8)                  | 0% (0)                      |
| E           | 42.11% (16)                           | 44.44% (4)                  | 50% (1)                     |
| DO          | 89.47% (34)                           | 55.56% (5)                  | 50% (1)                     |
| CTR         | 73.68% (28)                           | 77.78% (7)                  | 50% (1)                     |

Fig-1: Pie chart showing distribution of CURB 65 Score of the study population

Fig-2: Gram staining of sputum sample showing gram positive cocci in pair

Fig-3: Gram staining of sputum sample showing gram negative bacilli
**DISCUSSION**

CAP is a frequent cause of hospital admission and mortality in elderly patients worldwide. The clinical presentation, etiology, and outcome of community-acquired pneumonia in elderly differs from that of other population. In the present study, 80 patients of community-acquired pneumonia >60 years of age were included. The results of this study which has been presented in previously are discussed below.

Study population distribution: In our study 216 sputum samples and 4 bronco-alveolar lavage samples were collected from a total of 220 study population (comprising of 122(55.45%) from IPD, 75(34.10%) from OPD & 23(10.45%) from ICU) of CAP as per inclusion and exclusion criteria from medicine & chest department- which indicates a large number of CAP patients need hospitalization and even ICU admission.

According to one eastern Indian study conducted by Khadanga S et al., all of their CAP patients (464 no.) were hospitalized, among them ICU admission rate was 16.1% [14]. Our result coincide with their patient distribution.

Sputum Microscopy and Culture: In this study, the microbial diagnosis of CAP was confirmed by sputum culture only in 58.80% patients. This result is corresponding with Jain et al. study (45.8%) [15]. The overall rate of identification of microbial aetiology in other parts of India: 75.6% in Shimla [16], 47.7% in Chandigarh [17], or other parts of world 62% in UK [18], 68% in Singapore [19] and 56% in Philippines [20]. This could be due to the limited use of laboratory tests. In this study, we used sputum, BAL culture and microscopy as diagnostic tools to identify the aerobic bacterial pathogen causing pneumonia. Serology for both atypical and viral pathogens was not done at the time of this study.

In this study 127 (58.80%) pathogens were isolated by sputum culture. But this is another fact that even with the use of extensive laboratory testing and various invasive procedures in different studies, etiological confirmation could be achieved only in 45-75% patients [4, 15-18, 21, 22].

Decreased sputum positivity is due to prior use of antibiotics, inappropriate sputum production and non-productive cough.

Streptococcus pneumoniae has been identified as the commonest organism causing CAP all over the world [14, 23-30]. But some studies, over the last three decades, have reported higher incidence of gram-negative organisms among culture-positive pneumonias [4, 31]. Most of the patients from whom gram-negative bacteria was isolated were over 50 years of age, smokers or had COPD. It has been reported that old age, smoking and COPD impair pulmonary defences and pre-dispose to CAP caused by gram-negative bacteria.

In this study most commonly isolated pathogen was *Klebsiella pneumoniae* accounting for 20.4%. Next common was *Staphylococcus aureus* which accounts for 16.20% this was followed by other Gram-negative bacilli – *Pseudomonas aeruginosa* 8.30%, *Citrobacter koseri* 4.20%, *Escherichia coli* 3.00%, *Citrobacter freundii* 1.40% and *Haemophilus influenzae* 1%. *Streptococcus pneumoniae* and *Streptococcus pyogenes* was isolated in 4.20% and 0.9% of cases respectively. As per some Indian studies, over last three decades have reported higher incidence of Gram-negative organisms among culture positive community acquired pneumonia cases [4, 9, 15, 31, 33, 34].

The second commonest organism isolated from sputum culture was *staphylococcus aureus*. The high incidence of staphylococcus in CAP can be explained by spread of staphylococcus from hospital setting to community and staphylococcus complicating virus illness esp. influenza [9, 10].
Antibiotic sensitivity testing: The role of the microbiology laboratory in the diagnosis of CAP remains controversial. As per Gupta et al., [35] National pneumonia guidelines, yield of sputum culture varies from 34% to 86%. In our study, organism was found in 58.80% of sputum culture reports; it is still recommend sending a routine sputum culture with Gram stain to optimize antibiotic therapy for each individual patient as well as to monitor for drug-resistance among pathogens.

Choosing the proper antibiotics as initial empiric therapy & later streamlining as per the culture sensitivity pattern is critical in outcome of CAP. Important considerations include penetration into respiratory secretions, spectrum of activity and antimicrobial resistance. These factors limit the usefulness of drugs such as amoxicillin, erythromycin and trimethoprim-sulfamethoxazole.

Woodhead et al., [36] in a study found that in non-severe CAP oral β lactam antibiotics, macrolides, or fluoroquinolones are equally effective when judged staphylococci showed best sensitivity compared to others, and for gram positive cocci was ceftriaxone, clindamycin & levofloxacin. So these drugs can be started as an empirical therapy for treatment of CAP and thereafter according to the antibiotic susceptibility testing report, escalation and de-escalation can be done.

Source of Support: Nil
Conflict of Interest: Nil

REFERENCE
1. Reid PT, Innes JA. Respiratory disease. In: Colledge NR, Walker BR, Ralston SH, editors. Davidson’s Principles & Practice of Medicine. 21st edition. New York: Elsevier; 2010; 680-8.
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Daniel MM, Michael SN, Torres A, Whitney CG. Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adults. Clin Infect Dis. 2007;44(Supplement 2):S27-72.
3. Khadanga S, Tadepalli K, Thatoi PK, Behera SK. Changing bacteriological profile and mortality trends in community acquired pneumonia. J Glob Infect Dis. 2014;6(4):186–8.
4. Chintaman AC, Ghadage DP, Bhore AV. Bacteriological profile of community acquired pneumonia in a tertiary care hospital. Int J Curr Microbiol App Sci. 2017;6(4):190-4.
5. Kejriwal A, Shenoi AS, Pusukuru R, Sebastien C, Bhutta K. A clinical, bacteriological and radiological profile of community acquired pneumonia in Navi Mumbai, India. IOSR-JDMS. 2015;14(9):58-61.
6. Silla M, Babu GR, Rani NU. Clinical, etiological profile and outcome of hospitalized patients of community acquired pneumonia. IJBAMR. 2017;6(3):576-85.
7. Epidemiology of community acquired pneumonia. Supplement to Journal of the Association of Physicians of India. 2013;61:7-8.
8. Kotwani A, Kumar S, Swain PK, Suri JC, Gaur SN. Antimicrobial drug prescribing patterns for community-acquired pneumonia in hospitalized patients: A retrospective pilot study from New Delhi, India. Indian J Pharmacol. 2015;47(4):375-82.
9. Shah BA, Singh G, Naik MA, Dhobi GN. Bacteriological and clinical profile of community acquired pneumonia in hospitalised patients. Lung India. 2010;27(2):54-7.
10. Vanlalruati RSC, Devi M, Singh NB, Singh NT. A study of bacteriological profile (aerobic) and antimicrobial susceptibility of community acquired pneumonia cases. J Commun Dis. 2012;44(1):47-9.
11. Ali MK, Batchoun RG, Nour TM. Etiology of community-acquired pneumonia in hospitalized patients in Jordan. Saudi Med J. 2006;27:813-6.

CONCLUSION
Klebsiella pneumoniae was the most common pathogen incriminated in CAP, followed by Staphylococcus aureus. But in general the emergence of the higher incidence of Gram-negative organism especially Klebsiella pneumoniae has occurred in our geographical area.

In our study we found the most effective antibiotics for gram negative bacilli causing CAP was meropenem followed by piperacillin-tazobactum and amikacin, and for gram positive cocci was ceftriaxone, clindamycin & levofloxacin. So these drugs can be
12. Savalviya A, Sodavadiya KB, Mangukiya KK. Study of clinical and bacteriological profile of community acquired pneumonia (cap) and its complications. I.J.S.N. 2013;4(4):702-10.

13. Acharya VK, Padyana M, Unnikrishnan B, Anand R, Acharya PR, Juneja DJ. Microbiological profile and drug sensitivity pattern among community acquired pneumonia patients in a tertiary care center in Mangalore, Coastal Karnataka, India. Journal of Clinical and Diagnostic Research. 2014;8(6):MC04-MC06.

14. Sandeep KJ, Shiping J, Shushma T. Study of clinical, radiological and bacteriological profile of community acquired pneumonia in hospitalized patients of Gajra Raja Medical College, Gwalior. International Journal of Scientific Study. 2014;2(6):96-100.

15. Jain SK, Jain S, Trikha S. Study of clinical, radiological and bacteriological profile of community acquired pneumonia in hospitalized patients of Garja raja medical college, Gwalior, central India. Int. J. Sci. J. Study. 2014;2(6):96-100.

16. Bansal S, Kashyap S, Pali LS, Goel A. Clinical and bacteriological profile of community acquired pneumonia in Shimla, Himachal Pradesh. Indian J Chest Dis Allied Sci. 2004;46(1):17-22.

17. Oberoi A, Aggarwal A. Bacteriological profile, serology and antibiotic sensitivity pattern of microorganism from community acquired pneumonia. JK Science. 2006;8(2):79-82.

18. Howard LS, Sillis M, Pasteur MC, Kamath AV, Harrison BD. Microbiological profile of community acquired pneumonia in adults over the last 20 years. J infect. 2005;50(2):107-13.

19. Lee KH, Hui KP, Tan WC, Lim TK. Severe community acquired pneumonia in Singapore. Singapore medical journal. 1996;37:374-77.

20. Ong G, Antonio-Velmonte M, Mendoza MT. Etiologic Agents of Community-Acquired Pneumonia in the Adult: The PGH Experience. Phil J Microbial Infect Dis.1995; 24(2): 29-32.

21. Tadashi I, Toru H, Machiko A, Isao I, Makoto O. Etiology of community acquired pneumonia in hospitalized patients: a 3 year prospective study in Japan. Chest. 1998;114(6):1588-93.

22. Lieberman D, Schlaeffer F, Boldur I, Horowitz S, Friedman MG, Leononen M, Horovitz O, Mmanor E, Porath A. Multiple pathogens in adult patients admitted with community acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax. 1996;51(2):179-84.

23. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014; 33:1065-79.

24. Hamidreza N, Fereshte S, Mohammadreza S, Zahra M, Mehdi IN. Etiological diagnosis of community acquired pneumonia in adult patients. Jundishapur J Microbiol. 2015;8(8):227-80.

25. Fiberesima FP, Owuchekwa AC. Community acquired pneumonia in Port Harcourt Rivers state of Nigeria. Cent Afr J Med. 2008; 54(1-4):1-8.

26. Immanuel AM, Faustina P. Prevalence of bacterial pathogens isolated from sputum cultures of hospitalized adult patients with community acquired pneumonia at the Cape Coast Teaching Hospital Ghana. E3 Journal of Medicine Research. 2014; 3(5):58-61.

27. Tao LL., Hu BJ, He LX, Wei L, Xie HM, Wang BG, Li HY, Chen XH, Zhou CM. Etiology and antimicrobial resistance of community acquired pneumonia in adult patients in China. Chin Med J. 2012; 125(17):2967-72.

28. Al-Ghizawi GJ, Al-Sulami A, Hamadi SS. Profile of community and hospital acquired pneumonia cases admitted to basra general hospital, Iraq. East. Mediterr. Health J. 2006; 13(2):230-42.

29. Capoor MR, Nair D, Aggarwal P, Gupta B. Rapid diagnosis of community acquired pneumonia using the BacT/Alert 3D system. Braz J Infect Dis. 2006; 10(5):352-6.

30. Chawla K, Mukhopadhay C, Majumdar M,airy I. Bacteriological profile and their antibiogram from cases of acute exacerbations of chronic obstructive pulmonary disease: A hospital based study. J Clin Diagn Res. 2008;2:612-6.

31. Mythri S, Nataraju HV. Bacteriological profile of community acquired pneumonia. IOSR-JDMS. 2013; 12(2):16-9.

32. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000; 31(2):347-82.

33. Singh R, Kour H, Jindal SK, Aggarwal AN, Gupta D, Khan GQ, Magotra S. Global youth tobacco survey: A report from Jammu and Kashmir. JK Science. 2008;10(2):65-9.

34. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, Kolczak MS, Mreiman RF. Cigarette smoking and invasive pneumococcal disease. N. Engl. J. Med. 2000; 342(10):681-9.

35. Gupta D, Aggarwal R, Nath AA, Singh N, Mishra N, Khilnani GC, Samaria JK, Gaur SN, Jindal SK. Guidelines for Diagnosis and Management of Community and Hospital Acquired Pneumonia in Adults: Joint ICS/NCCP (I) Recommendations. Lung India. 2012; 29:S27-S62.

36. Woodhead M, Verheji TJM. A step forward in the everyday management of adults with community acquired pneumonia. BMJ. 2005; 330(7489):460.